General Catalyst and Reid Hoffman led a $24.6m seed round in Manas AI.

General Catalyst, a venture capital firm, and Reid Hoffman led a $24.6m seed round in Manas AI, a full-stack, AI-driven drug discovery company, with participation from Greylock. "As a former CEO in the biopharma industry, I'm very familiar with the challenges of the highly complex and resource-intensive therapeutic discovery model. Manas AI has the potential to compress the timeline to discovery of effective drug candidates while increasing the likelihood of success in clinical trials. This is a unique opportunity to dramatically change the drug discovery landscape and make a positive impact on billions of people around the world," Ken Frazier, General Catalyst Chairman of Health Assurance Initiatives.